Research programme: inflammation therapy - PLIVAAlternative Names: Inflammation therapy research programme - PLIVA
Latest Information Update: 16 Aug 2007
At a glance
- Originator PLIVA d.d.
- Mechanism of Action Cytokine inhibitors; Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Inflammation; Rheumatoid arthritis
Most Recent Events
- 20 Feb 2001 Preclinical development for Rheumatoid arthritis in Croatia (PO)
- 20 Feb 2001 Preclinical development for Inflammation in Croatia (PO)